Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.
P Malfertheiner, F Megraud, C A O'Morain...
https://pubmed.ncbi.nlm.nih.gov/27707777Actively Recruiting
Phase Not Applicable
Age: 19Years +
All Genders
ID07045688
Efficacy of Vonoprazan Based Dual and Triple Therapy for Naive Patient With Helicobacter Pylori Infection
Led by Sohag University · Updated on 2025-07-01
150
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of vonoprazan-based dual and triple therapies compared to proton pump inhibitor (PPI) based triple therapy for treating patients with Helicobacter pylori infection who have not received prior treatment. The study is conducted by Sohag University and aims to determine which treatment best eradicates this infection in naive patients. Participants will be randomly assigned to one of three groups: vonoprazan-based dual therapy, vonoprazan-based triple therapy, or PPI-based triple therapy. Each therapy is designed to eliminate Helicobacter pylori infection, and the study compares their relative effectiveness. Treatments will be administered according to defined protocols for each group. During the study, participants will receive medical treatment and be monitored over time to assess the success of the eradication, with primary outcomes measured four weeks after completing therapy. The study involves follow-up visits to confirm infection status and track adherence to treatment. The total duration and detailed participant involvement align with standard clinical evaluation of treatment efficacy.
CONDITIONS
Brief Title
Efficacy of Vonoprazan Based Dual and Triple Therapy for Patient With Helicobacter Pylori Infection
Who Can Participate
Age: 19Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years old
- Confirmed Helicobacter pylori infection by histopathology or non-invasive tests such as stool antigen test
You will not qualify if you...
- Previous treatment for Helicobacter pylori infection
- Known allergies to study medications or their components
- Unable to complete the full course of treatment
- Missed follow-up visits
- Refusal or neglect of test to confirm Helicobacter pylori cure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 4 weeks
Participants receive one of the study drug therapies aimed at eradicating Helicobacter pylori infection.
Weekly visits for up to 4 weeks
Follow-up
Duration - 4 weeks after treatment
Participants are monitored 4 weeks after completing treatment to assess the efficacy of the therapy.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Sohag University Hospital
Sohag, Egypt
Actively Recruiting
Loading map...
Research Team
A
Andrew K Wadea, Resident
H
Hamdy S Mohammed, Professor
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
William D Chey, Grigorios I Leontiadis, Colin W Howden...
https://pubmed.ncbi.nlm.nih.gov/28071659Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population.
Erick A Argueta, Mohd Amer Alsamman, Steven F Moss...
https://pubmed.ncbi.nlm.nih.gov/33577874